{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:12:56Z","timestamp":1791252776701,"version":"4.1.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["MNESYS (PE0000006)"],"award-info":[{"award-number":["MNESYS (PE0000006)"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013209","name":"Hellenic Foundation for Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["#453989101"],"award-info":[{"award-number":["#453989101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["#505805397"],"award-info":[{"award-number":["#505805397"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 1116 B8"],"award-info":[{"award-number":["CRC 1116 B8"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RTG 2989"],"award-info":[{"award-number":["RTG 2989"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["CA22169"],"award-info":[{"award-number":["CA22169"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The term cardiac amyloidosis (CA) refers to the accumulation of extracellular amyloid deposits in the heart because of different conditions often affecting multiple organs including brain, kidney and liver. Notably, cardiac involvement significantly impacts prognosis of amyloidosis, with cardiac biomarkers playing a pivotal role in prognostic stratification. Therapeutic management poses a challenge due to limited response to conventional heart failure therapies, necessitating targeted approaches aimed at preventing, halting or reversing amyloid deposition. Mechanisms underlying organ damage in CA are multifactorial, involving proteotoxicity, oxidative stress, and mechanical interference. While the role of inflammation in CA remains incompletely understood, emerging evidence suggests its potential contribution to disease progression as well as its utility as a therapeutic target. This review reports on the cardiac involvement in systemic amyloidosis, its prognostic role and how to assess it. Current and emerging therapies will be critically discussed underscoring the need for further efforts aiming at elucidating CA pathophysiology. The emerging evidence suggesting the contribution of inflammation to disease progression and its prognostic role will also be reviewed possibly offering insights into novel therapeutic avenues for CA.<\/jats:p>","DOI":"10.1007\/s00392-024-02522-2","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T11:39:16Z","timestamp":1724326756000},"page":"685-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?"],"prefix":"10.1007","volume":"115","author":[{"given":"Ilaria Anna","family":"Bellofatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota Efstathia","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Canepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Heusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kleinbongard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Maack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno K.","family":"Podesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Stamatelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vilahur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-7975","authenticated-orcid":false,"given":"Luca","family":"Liberale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"2522_CR1","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126:1286\u20131300. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.078915","journal-title":"Circulation"},{"key":"2522_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cjca.2019.12.033","volume":"36","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM, Falk RH (2020) Amyloidosis as a systemic disease in context. Can J Cardiol 36:396\u2013407. https:\/\/doi.org\/10.1016\/j.cjca.2019.12.033","journal-title":"Can J Cardiol"},{"key":"2522_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","volume":"29","author":"JN Buxbaum","year":"2022","unstructured":"Buxbaum JN et al (2022) Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 29:213\u2013219. https:\/\/doi.org\/10.1080\/13506129.2022.2147636","journal-title":"Amyloid"},{"key":"2522_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26165091","author":"H Koike","year":"2021","unstructured":"Koike H, Iguchi Y, Sahashi K, Katsuno M (2021) Significance of oligomeric and fibrillar species in amyloidosis: insights into pathophysiology and treatment. Molecules. https:\/\/doi.org\/10.3390\/molecules26165091","journal-title":"Molecules"},{"key":"2522_CR5","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387:2641\u20132654. https:\/\/doi.org\/10.1016\/S0140-6736(15)01274-X","journal-title":"Lancet"},{"key":"2522_CR6","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1097\/HS9.0000000000000454","volume":"4","author":"D Fotiou","year":"2020","unstructured":"Fotiou D, Dimopoulos MA, Kastritis E (2020) Systemic AL amyloidosis: current approaches to diagnosis and management. Hemasphere 4:e454. https:\/\/doi.org\/10.1097\/HS9.0000000000000454","journal-title":"Hemasphere"},{"key":"2522_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM et al (2019) Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 7:709\u2013716. https:\/\/doi.org\/10.1016\/j.jchf.2019.04.010","journal-title":"JACC Heart Fail"},{"key":"2522_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"2522_CR9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","volume":"165","author":"B Ng","year":"2005","unstructured":"Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165:1425\u20131429. https:\/\/doi.org\/10.1001\/archinte.165.12.1425","journal-title":"Arch Intern Med"},{"key":"2522_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2016.1221815","volume":"23","author":"T Damy","year":"2016","unstructured":"Damy T et al (2016) Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. Amyloid 23:194\u2013202. https:\/\/doi.org\/10.1080\/13506129.2016.1221815","journal-title":"Amyloid"},{"key":"2522_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","volume":"4","author":"T Bhuiyan","year":"2011","unstructured":"Bhuiyan T et al (2011) Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: transthyretin cardiac amyloid study (TRACS). Circ Heart Fail 4:121\u2013128. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.910455","journal-title":"Circ Heart Fail"},{"key":"2522_CR12","doi-asserted-by":"publisher","first-page":"100519","DOI":"10.1016\/j.ijcha.2020.100519","volume":"28","author":"M Papathanasiou","year":"2020","unstructured":"Papathanasiou M et al (2020) Diagnosing cardiac amyloidosis in every-day practice: a practical guide for the cardiologist. Int J Cardiol Heart Vasc 28:100519. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100519","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2522_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","volume":"8","author":"VS Hahn","year":"2020","unstructured":"Hahn VS et al (2020) Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail 8:712\u2013724. https:\/\/doi.org\/10.1016\/j.jchf.2020.04.007","journal-title":"JACC Heart Fail"},{"key":"2522_CR14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ehjci\/jey225","volume":"20","author":"C Binder","year":"2019","unstructured":"Binder C et al (2019) Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. Eur Heart J Cardiovasc Imaging 20:512\u2013524. https:\/\/doi.org\/10.1093\/ehjci\/jey225","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2522_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583\u2013596. https:\/\/doi.org\/10.1056\/NEJMra023144","journal-title":"N Engl J Med"},{"key":"2522_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-024-00661-1","author":"S Wernhart","year":"2024","unstructured":"Wernhart S, Michel L, Carpinteiro A, Luedike P, Rassaf T (2024) (Non)-exertional variables of cardiopulmonary exercise testing in heart failure with and without cardiac amyloidosis. Curr Heart Fail Rep. https:\/\/doi.org\/10.1007\/s11897-024-00661-1","journal-title":"Curr Heart Fail Rep"},{"key":"2522_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.36628\/ijhf.2024.0002","volume":"6","author":"SR Lee","year":"2024","unstructured":"Lee SR, Choi JM (2024) Is it time to expand the indication of DOAC to patients with cardiac amyloidosis and atrial fibrillation? Int J Heart Fail 6:44\u201345. https:\/\/doi.org\/10.36628\/ijhf.2024.0002","journal-title":"Int J Heart Fail"},{"key":"2522_CR18","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.cpcardiol.2022.101571","volume":"48","author":"S Bukhari","year":"2023","unstructured":"Bukhari S, Oliveros E, Parekh H, Farmakis D (2023) Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis. Curr Probl Cardiol 48:101571. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101571","journal-title":"Curr Probl Cardiol"},{"key":"2522_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/eurheartj\/ehz057","volume":"40","author":"MP van den Berg","year":"2019","unstructured":"van den Berg MP et al (2019) Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. Eur Heart J 40:1287\u20131293. https:\/\/doi.org\/10.1093\/eurheartj\/ehz057","journal-title":"Eur Heart J"},{"key":"2522_CR20","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","volume":"119","author":"D Feng","year":"2009","unstructured":"Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119:2490\u20132497. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.785014","journal-title":"Circulation"},{"key":"2522_CR21","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/ehf2.13851","volume":"9","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M et al (2022) Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis. ESC Heart Fail 9:1740\u20131748. https:\/\/doi.org\/10.1002\/ehf2.13851","journal-title":"ESC Heart Fail"},{"key":"2522_CR22","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","volume":"41","author":"PR Scully","year":"2020","unstructured":"Scully PR et al (2020) Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J 41:2759\u20132767. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa170","journal-title":"Eur Heart J"},{"key":"2522_CR23","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ejhf.1756","volume":"22","author":"C Nitsche","year":"2020","unstructured":"Nitsche C et al (2020) Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail 22:1852\u20131862. https:\/\/doi.org\/10.1002\/ejhf.1756","journal-title":"Eur J Heart Fail"},{"key":"2522_CR24","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano A et al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38:2879\u20132887. https:\/\/doi.org\/10.1093\/eurheartj\/ehx350","journal-title":"Eur Heart J"},{"key":"2522_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/157488608783333989","volume":"3","author":"MA Perazella","year":"2008","unstructured":"Perazella MA (2008) Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 3:67\u201375. https:\/\/doi.org\/10.2174\/157488608783333989","journal-title":"Curr Drug Saf"},{"key":"2522_CR26","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C et al (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120:1203\u20131212. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.843334","journal-title":"Circulation"},{"key":"2522_CR27","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","volume":"74","author":"J Ternacle","year":"2019","unstructured":"Ternacle J et al (2019) Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol 74:2638\u20132651. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.056","journal-title":"J Am Coll Cardiol"},{"key":"2522_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2:358\u2013367. https:\/\/doi.org\/10.1016\/j.jchf.2014.03.009","journal-title":"JACC Heart Fail"},{"key":"2522_CR29","doi-asserted-by":"publisher","first-page":"e020358","DOI":"10.1161\/JAHA.120.020358","volume":"10","author":"A Pucci","year":"2021","unstructured":"Pucci A et al (2021) Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. J Am Heart Assoc 10:e020358. https:\/\/doi.org\/10.1161\/JAHA.120.020358","journal-title":"J Am Heart Assoc"},{"key":"2522_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-022-00909-8","volume":"117","author":"G Heusch","year":"2022","unstructured":"Heusch G (2022) Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol 117:1. https:\/\/doi.org\/10.1007\/s00395-022-00909-8","journal-title":"Basic Res Cardiol"},{"key":"2522_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1161\/CIRCRESAHA.119.314862","volume":"125","author":"K Stamatelopoulos","year":"2019","unstructured":"Stamatelopoulos K et al (2019) Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis. Circ Res 125:744\u2013758. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.314862","journal-title":"Circ Res"},{"key":"2522_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","volume":"29","author":"A Aimo","year":"2024","unstructured":"Aimo A et al (2024) Sex differences in transthyretin cardiac amyloidosis. Heart Fail Rev 29:321\u2013330. https:\/\/doi.org\/10.1007\/s10741-023-10339-w","journal-title":"Heart Fail Rev"},{"key":"2522_CR33","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/JCO.2001.19.14.3350","volume":"19","author":"A Dispenzieri","year":"2001","unstructured":"Dispenzieri A et al (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19:3350\u20133356. https:\/\/doi.org\/10.1200\/JCO.2001.19.14.3350","journal-title":"J Clin Oncol"},{"key":"2522_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","volume":"13","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM et al (2020) Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease? JACC Cardiovasc Imaging 13:1325\u20131336. https:\/\/doi.org\/10.1016\/j.jcmg.2020.02.025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2522_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ehjci\/jeaa063","volume":"21","author":"R Jurcut","year":"2020","unstructured":"Jurcut R et al (2020) Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging 21:833\u2013844. https:\/\/doi.org\/10.1093\/ehjci\/jeaa063","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2522_CR36","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD et al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799\u20132806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589","journal-title":"Eur Heart J"},{"key":"2522_CR37","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68:1014\u20131020. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033","journal-title":"J Am Coll Cardiol"},{"key":"2522_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989\u2013995. https:\/\/doi.org\/10.1200\/JCO.2011.38.5724","journal-title":"J Clin Oncol"},{"key":"2522_CR39","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","volume":"104","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A et al (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881\u20131887. https:\/\/doi.org\/10.1182\/blood-2004-01-0390","journal-title":"Blood"},{"key":"2522_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ehjci\/jead188","volume":"25","author":"F Duca","year":"2023","unstructured":"Duca F et al (2023) Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry. Eur Heart J Cardiovasc Imaging 25:95\u2013104. https:\/\/doi.org\/10.1093\/ehjci\/jead188","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2522_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1148\/radiol.2015141744","volume":"277","author":"M Fontana","year":"2015","unstructured":"Fontana M et al (2015) Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 277:388\u2013397. https:\/\/doi.org\/10.1148\/radiol.2015141744","journal-title":"Radiology"},{"key":"2522_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020368","author":"F Duca","year":"2024","unstructured":"Duca F et al (2024) Amyloid burden correlates with electrocardiographic findings in patients with cardiac amyloidosis-insights from histology and cardiac magnetic resonance imaging. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13020368","journal-title":"J Clin Med"},{"key":"2522_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijcard.2019.09.042","volume":"300","author":"DJ Lenihan","year":"2020","unstructured":"Lenihan DJ, Jimenez J (2020) Cardiac amyloidosis and hypertrophic cardiomyopathy: \u201cyou always have time to make an accurate diagnosis!\u201d Int J Cardiol 300:205\u2013206. https:\/\/doi.org\/10.1016\/j.ijcard.2019.09.042","journal-title":"Int J Cardiol"},{"key":"2522_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","volume":"300","author":"N Maurizi","year":"2020","unstructured":"Maurizi N et al (2020) Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 300:191\u2013195. https:\/\/doi.org\/10.1016\/j.ijcard.2019.07.051","journal-title":"Int J Cardiol"},{"key":"2522_CR45","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T et al (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 37:1826\u20131834. https:\/\/doi.org\/10.1093\/eurheartj\/ehv583","journal-title":"Eur Heart J"},{"key":"2522_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","volume":"20","author":"M Fontana","year":"2015","unstructured":"Fontana M, Chung R, Hawkins PN, Moon JC (2015) Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 20:133\u2013144. https:\/\/doi.org\/10.1007\/s10741-014-9470-7","journal-title":"Heart Fail Rev"},{"key":"2522_CR47","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1001\/jamacardio.2023.2010","volume":"8","author":"A Ioannou","year":"2023","unstructured":"Ioannou A et al (2023) Tracking treatment response in cardiac light-chain amyloidosis with native T1 mapping. JAMA Cardiol 8:848\u2013852. https:\/\/doi.org\/10.1001\/jamacardio.2023.2010","journal-title":"JAMA Cardiol"},{"key":"2522_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","volume":"7","author":"JN Dungu","year":"2014","unstructured":"Dungu JN et al (2014) CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 7:133\u2013142. https:\/\/doi.org\/10.1016\/j.jcmg.2013.08.015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2522_CR49","doi-asserted-by":"publisher","first-page":"101573","DOI":"10.1016\/j.cpcardiol.2022.101573","volume":"48","author":"A Briasoulis","year":"2023","unstructured":"Briasoulis A et al (2023) Diagnostic and prognostic value of non-late gadolinium enhancement cardiac magnetic resonance parameters in cardiac amyloidosis. Curr Probl Cardiol 48:101573. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101573","journal-title":"Curr Probl Cardiol"},{"key":"2522_CR50","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/ehf2.13443","volume":"8","author":"RD Adam","year":"2021","unstructured":"Adam RD et al (2021) Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail 8:2380\u20132396. https:\/\/doi.org\/10.1002\/ehf2.13443","journal-title":"ESC Heart Fail"},{"key":"2522_CR51","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1073\/pnas.1919199116","volume":"117","author":"P Jordan","year":"2020","unstructured":"Jordan P (2020) Chronic well leakage probability relative to basin and fluid characteristics. Proc Natl Acad Sci U S A 117:1249\u20131251. https:\/\/doi.org\/10.1073\/pnas.1919199116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2522_CR52","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/s1885-5857(09)72236-4","volume":"62","author":"M Gomez-Bueno","year":"2009","unstructured":"Gomez-Bueno M et al (2009) Cardiac amyloidosis: the importance of a multidisciplinary approach. Rev Esp Cardiol 62:698\u2013702. https:\/\/doi.org\/10.1016\/s1885-5857(09)72236-4","journal-title":"Rev Esp Cardiol"},{"key":"2522_CR53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10741-020-10062-w","volume":"26","author":"V Bistola","year":"2021","unstructured":"Bistola V et al (2021) Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Fail Rev 26:861\u2013879. https:\/\/doi.org\/10.1007\/s10741-020-10062-w","journal-title":"Heart Fail Rev"},{"key":"2522_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14160","author":"IA Bellofatto","year":"2024","unstructured":"Bellofatto IA et al (2024) Early diagnosis and management of cardiac amyloidosis: a clinical perspective. Eur J Clin Invest. https:\/\/doi.org\/10.1111\/eci.14160","journal-title":"Eur J Clin Invest"},{"key":"2522_CR55","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 42:1554\u20131568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"2522_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.07.022","volume":"67","author":"AS Manolis","year":"2019","unstructured":"Manolis AS, Manolis AA, Manolis TA, Melita H (2019) Cardiac amyloidosis: an underdiagnosed\/underappreciated disease. Eur J Intern Med 67:1\u201313. https:\/\/doi.org\/10.1016\/j.ejim.2019.07.022","journal-title":"Eur J Intern Med"},{"key":"2522_CR57","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA et al (2015) Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol 66:2451\u20132466. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.075","journal-title":"J Am Coll Cardiol"},{"key":"2522_CR58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jcmg.2020.06.017","volume":"14","author":"TH Schindler","year":"2021","unstructured":"Schindler TH, Sharma V, Imperiale A (2021) (18) F-florbetaben and PET\/CT holds promise for the identification and differentiation among cardiac amyloidosis entities. JACC Cardiovasc Imaging 14:256\u2013258. https:\/\/doi.org\/10.1016\/j.jcmg.2020.06.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2522_CR59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","volume":"27","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Ha S, Kim YI (2020) Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis. J Nucl Cardiol 27:123\u2013132. https:\/\/doi.org\/10.1007\/s12350-018-1365-x","journal-title":"J Nucl Cardiol"},{"key":"2522_CR60","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenblum H, Maurer MS (2021) Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 128:1554\u20131575. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318187","journal-title":"Circ Res"},{"key":"2522_CR61","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","volume":"16","author":"S Ihne","year":"2019","unstructured":"Ihne S, Morbach C, Obici L, Palladini G, Stork S (2019) Amyloidosis in heart failure. Curr Heart Fail Rep 16:285\u2013303. https:\/\/doi.org\/10.1007\/s11897-019-00446-x","journal-title":"Curr Heart Fail Rep"},{"key":"2522_CR62","doi-asserted-by":"publisher","first-page":"15661","DOI":"10.1038\/s41598-017-15424-3","volume":"7","author":"E Imperlini","year":"2017","unstructured":"Imperlini E et al (2017) Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep 7:15661. https:\/\/doi.org\/10.1038\/s41598-017-15424-3","journal-title":"Sci Rep"},{"key":"2522_CR63","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","volume":"104","author":"R Liao","year":"2001","unstructured":"Liao R et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104:1594\u20131597","journal-title":"Circulation"},{"key":"2522_CR64","doi-asserted-by":"publisher","first-page":"H1158","DOI":"10.1152\/ajpheart.00788.2018","volume":"316","author":"S Mishra","year":"2019","unstructured":"Mishra S et al (2019) Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. Am J Physiol Heart Circ Physiol 316:H1158\u2013H1166. https:\/\/doi.org\/10.1152\/ajpheart.00788.2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2522_CR65","doi-asserted-by":"publisher","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","volume":"305","author":"S Mishra","year":"2013","unstructured":"Mishra S et al (2013) Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 305:H95-103. https:\/\/doi.org\/10.1152\/ajpheart.00186.2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2522_CR66","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J et al (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 107:4188\u20134193. https:\/\/doi.org\/10.1073\/pnas.0912263107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2522_CR67","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","volume":"94","author":"DA Brenner","year":"2004","unstructured":"Brenner DA et al (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94:1008\u20131010. https:\/\/doi.org\/10.1161\/01.RES.0000126569.75419.74","journal-title":"Circ Res"},{"key":"2522_CR68","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","volume":"123","author":"L Diomede","year":"2014","unstructured":"Diomede L et al (2014) A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 123:3543\u20133552. https:\/\/doi.org\/10.1182\/blood-2013-10-525634","journal-title":"Blood"},{"key":"2522_CR69","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00395-013-0378-5","volume":"108","author":"J Guan","year":"2013","unstructured":"Guan J et al (2013) Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 108:378. https:\/\/doi.org\/10.1007\/s00395-013-0378-5","journal-title":"Basic Res Cardiol"},{"key":"2522_CR70","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.15252\/emmm.201404190","volume":"6","author":"J Guan","year":"2014","unstructured":"Guan J et al (2014) Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med 6:1493\u20131507. https:\/\/doi.org\/10.15252\/emmm.201404190","journal-title":"EMBO Mol Med"},{"key":"2522_CR71","doi-asserted-by":"publisher","first-page":"102894","DOI":"10.1016\/j.redox.2023.102894","volume":"67","author":"G Heusch","year":"2023","unstructured":"Heusch G et al (2023) Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. Redox Biol 67:102894. https:\/\/doi.org\/10.1016\/j.redox.2023.102894","journal-title":"Redox Biol"},{"key":"2522_CR72","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1073\/pnas.0400062101","volume":"101","author":"N Reixach","year":"2004","unstructured":"Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN (2004) Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 101:2817\u20132822. https:\/\/doi.org\/10.1073\/pnas.0400062101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2522_CR73","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20140155","author":"P Manral","year":"2015","unstructured":"Manral P, Reixach N (2015) Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20140155"},{"key":"2522_CR74","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","volume":"52","author":"L Zhao","year":"2013","unstructured":"Zhao L, Buxbaum JN, Reixach N (2013) Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52:1913\u20131926. https:\/\/doi.org\/10.1021\/bi301313b","journal-title":"Biochemistry"},{"key":"2522_CR75","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2011.04.133","volume":"410","author":"S Bourgault","year":"2011","unstructured":"Bourgault S et al (2011) Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 410:707\u2013713. https:\/\/doi.org\/10.1016\/j.bbrc.2011.04.133","journal-title":"Biochem Biophys Res Commun"},{"key":"2522_CR76","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/s0002-9440(10)63050-7","volume":"159","author":"MM Sousa","year":"2001","unstructured":"Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159:1993\u20132000. https:\/\/doi.org\/10.1016\/s0002-9440(10)63050-7","journal-title":"Am J Pathol"},{"key":"2522_CR77","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","volume":"107","author":"G Palladini","year":"2006","unstructured":"Palladini G et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854\u20133858. https:\/\/doi.org\/10.1182\/blood-2005-11-4385","journal-title":"Blood"},{"key":"2522_CR78","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541\u20134549. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"key":"2522_CR79","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/13506129.2012.733741","volume":"19","author":"JT Shin","year":"2012","unstructured":"Shin JT et al (2012) Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid 19:191\u2013196. https:\/\/doi.org\/10.3109\/13506129.2012.733741","journal-title":"Amyloid"},{"key":"2522_CR80","doi-asserted-by":"publisher","first-page":"1008449","DOI":"10.3389\/fimmu.2022.1008449","volume":"13","author":"G Martinez-Rivas","year":"2022","unstructured":"Martinez-Rivas G, Bender S, Sirac C (2022) Understanding AL amyloidosis with a little help from in vivo models. Front Immunol 13:1008449. https:\/\/doi.org\/10.3389\/fimmu.2022.1008449","journal-title":"Front Immunol"},{"key":"2522_CR81","doi-asserted-by":"publisher","first-page":"26623","DOI":"10.1038\/srep26623","volume":"6","author":"N Ferreira","year":"2016","unstructured":"Ferreira N, Goncalves NP, Saraiva MJ, Almeida MR (2016) Curcumin: a multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Sci Rep 6:26623. https:\/\/doi.org\/10.1038\/srep26623","journal-title":"Sci Rep"},{"key":"2522_CR82","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.neurobiolaging.2008.04.001","volume":"31","author":"SD Santos","year":"2010","unstructured":"Santos SD, Fernandes R, Saraiva MJ (2010) The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol Aging 31:280\u2013289. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2008.04.001","journal-title":"Neurobiol Aging"},{"key":"2522_CR83","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1038\/s41467-021-27416-z","volume":"12","author":"I Slamova","year":"2021","unstructured":"Slamova I et al (2021) Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nat Commun 12:7112. https:\/\/doi.org\/10.1038\/s41467-021-27416-z","journal-title":"Nat Commun"},{"key":"2522_CR84","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/labinvest.2011.195","volume":"92","author":"M Ueda","year":"2012","unstructured":"Ueda M et al (2012) Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: a valid pathological model of the human disease. Lab Invest 92:474\u2013484. https:\/\/doi.org\/10.1038\/labinvest.2011.195","journal-title":"Lab Invest"},{"key":"2522_CR85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/MCA.0000000000001198","volume":"34","author":"X Guo","year":"2023","unstructured":"Guo X, Ma L (2023) Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. Coron Artery Dis 34:66\u201377. https:\/\/doi.org\/10.1097\/MCA.0000000000001198","journal-title":"Coron Artery Dis"},{"key":"2522_CR86","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM et al (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383:1838\u20131847. https:\/\/doi.org\/10.1056\/NEJMoa2021372","journal-title":"N Engl J Med"},{"key":"2522_CR87","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"2522_CR88","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","volume":"109","author":"DL Mann","year":"2004","unstructured":"Mann DL et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594\u20131602. https:\/\/doi.org\/10.1161\/01.CIR.0000124490.27666.B2","journal-title":"Circulation"},{"key":"2522_CR89","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.disamonth.2010.06.001","volume":"56","author":"RJ Castellani","year":"2010","unstructured":"Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56:484\u2013546. https:\/\/doi.org\/10.1016\/j.disamonth.2010.06.001","journal-title":"Dis Mon"},{"key":"2522_CR90","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ni.1636","volume":"9","author":"A Halle","year":"2008","unstructured":"Halle A et al (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857\u2013865. https:\/\/doi.org\/10.1038\/ni.1636","journal-title":"Nat Immunol"},{"key":"2522_CR91","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.bbr.2016.06.001","volume":"311","author":"DH Kim","year":"2016","unstructured":"Kim DH et al (2016) Infliximab ameliorates AD-associated object recognition memory impairment. Behav Brain Res 311:384\u2013391. https:\/\/doi.org\/10.1016\/j.bbr.2016.06.001","journal-title":"Behav Brain Res"},{"key":"2522_CR92","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mp.2012.168","volume":"18","author":"JH Ledo","year":"2013","unstructured":"Ledo JH et al (2013) Amyloid-beta oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry 18:1053\u20131054. https:\/\/doi.org\/10.1038\/mp.2012.168","journal-title":"Mol Psychiatry"},{"key":"2522_CR93","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.brainresbull.2018.07.019","volume":"142","author":"HY Zhang","year":"2018","unstructured":"Zhang HY et al (2018) Reduction of amyloid beta by Abeta3-10-KLH vaccine also decreases tau pathology in 3xTg-AD mice. Brain Res Bull 142:233\u2013240. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.07.019","journal-title":"Brain Res Bull"},{"issue":"862","key":"2522_CR94","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1016\/j.jamda.2016.06.009","volume":"17","author":"RM Sterner","year":"2016","unstructured":"Sterner RM, Takahashi PY, Yu Ballard AC (2016) Active vaccines for alzheimer disease treatment. J Am Med Dir Assoc 17(862):e811-865. https:\/\/doi.org\/10.1016\/j.jamda.2016.06.009","journal-title":"J Am Med Dir Assoc"},{"key":"2522_CR95","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1039\/d2sc01278b","volume":"13","author":"T Sinnige","year":"2022","unstructured":"Sinnige T (2022) Molecular mechanisms of amyloid formation in living systems. Chem Sci 13:7080\u20137097. https:\/\/doi.org\/10.1039\/d2sc01278b","journal-title":"Chem Sci"},{"key":"2522_CR96","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41375-019-0640-4","volume":"34","author":"TL Jordan","year":"2020","unstructured":"Jordan TL et al (2020) Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia 34:1383\u20131393. https:\/\/doi.org\/10.1038\/s41375-019-0640-4","journal-title":"Leukemia"},{"key":"2522_CR97","doi-asserted-by":"publisher","first-page":"145293","DOI":"10.1155\/2015\/145293","volume":"2015","author":"S Hermouet","year":"2015","unstructured":"Hermouet S, Bigot-Corbel E, Gardie B (2015) Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm 2015:145293. https:\/\/doi.org\/10.1155\/2015\/145293","journal-title":"Mediators Inflamm"},{"key":"2522_CR98","doi-asserted-by":"publisher","first-page":"1852517","DOI":"10.1155\/2017\/1852517","volume":"2017","author":"C Musolino","year":"2017","unstructured":"Musolino C et al (2017) Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Mediators Inflamm 2017:1852517. https:\/\/doi.org\/10.1155\/2017\/1852517","journal-title":"Mediators Inflamm"},{"key":"2522_CR99","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/sj.leu.2400873","volume":"12","author":"KA Donovan","year":"1998","unstructured":"Donovan KA et al (1998) Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia 12:593\u2013600. https:\/\/doi.org\/10.1038\/sj.leu.2400873","journal-title":"Leukemia"},{"key":"2522_CR100","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.ekir.2021.02.026","volume":"6","author":"C Sirac","year":"2021","unstructured":"Sirac C, Batuman V, Sanders PW (2021) The proximal tubule toxicity of immunoglobulin light chains. Kidney Int Rep 6:1225\u20131231. https:\/\/doi.org\/10.1016\/j.ekir.2021.02.026","journal-title":"Kidney Int Rep"},{"key":"2522_CR101","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/labinvest.3780116","volume":"80","author":"MM Sousa","year":"2000","unstructured":"Sousa MM, Yan SD, Stern D, Saraiva MJ (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 80:1101\u20131110. https:\/\/doi.org\/10.1038\/labinvest.3780116","journal-title":"Lab Invest"},{"key":"2522_CR102","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","volume":"21","author":"MM Sousa","year":"2001","unstructured":"Sousa MM et al (2001) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 21:7576\u20137586. https:\/\/doi.org\/10.1523\/JNEUROSCI.21-19-07576.2001","journal-title":"J Neurosci"},{"key":"2522_CR103","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1096\/fj.11-189571","volume":"26","author":"JN Buxbaum","year":"2012","unstructured":"Buxbaum JN et al (2012) Why are some amyloidoses systemic? Does hepatic \u201cchaperoning at a distance\u201d prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J 26:2283\u20132293. https:\/\/doi.org\/10.1096\/fj.11-189571","journal-title":"FASEB J"},{"key":"2522_CR104","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/nan.12477","volume":"44","author":"HW Kan","year":"2018","unstructured":"Kan HW et al (2018) Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser. Neuropathol Appl Neurobiol 44:673\u2013686. https:\/\/doi.org\/10.1111\/nan.12477","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2522_CR105","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41374-017-0019-y","volume":"98","author":"X Li","year":"2018","unstructured":"Li X et al (2018) Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci. Lab Invest 98:512\u2013524. https:\/\/doi.org\/10.1038\/s41374-017-0019-y","journal-title":"Lab Invest"},{"key":"2522_CR106","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s10753-015-0214-1","volume":"38","author":"Y Hayashi","year":"2015","unstructured":"Hayashi Y et al (2015) Elevated endomyocardial biopsy macrophage-related markers in intractable myocardial diseases. Inflammation 38:2288\u20132299. https:\/\/doi.org\/10.1007\/s10753-015-0214-1","journal-title":"Inflammation"},{"key":"2522_CR107","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nri2215","volume":"8","author":"H Kono","year":"2008","unstructured":"Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8:279\u2013289. https:\/\/doi.org\/10.1038\/nri2215","journal-title":"Nat Rev Immunol"},{"key":"2522_CR108","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P Matzinger","year":"2002","unstructured":"Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301\u2013305. https:\/\/doi.org\/10.1126\/science.1071059","journal-title":"Science"},{"key":"2522_CR109","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s00018-012-1245-5","volume":"70","author":"A Gustot","year":"2013","unstructured":"Gustot A et al (2013) Activation of innate immunity by lysozyme fibrils is critically dependent on cross-beta sheet structure. Cell Mol Life Sci 70:2999\u20133012. https:\/\/doi.org\/10.1007\/s00018-012-1245-5","journal-title":"Cell Mol Life Sci"},{"key":"2522_CR110","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaccao.2020.08.013","volume":"2","author":"TV Kourelis","year":"2020","unstructured":"Kourelis TV et al (2020) A proteomic atlas of cardiac amyloid plaques. JACC CardioOncol 2:632\u2013643. https:\/\/doi.org\/10.1016\/j.jaccao.2020.08.013","journal-title":"JACC CardioOncol"},{"key":"2522_CR111","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ejhf.1039","volume":"20","author":"CS Siegismund","year":"2018","unstructured":"Siegismund CS et al (2018) Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail 20:751\u2013757. https:\/\/doi.org\/10.1002\/ejhf.1039","journal-title":"Eur J Heart Fail"},{"key":"2522_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.01.001","author":"A Porcari","year":"2024","unstructured":"Porcari A, Sinagra G, Gillmore JD, Fontana M, Hawkins PN (2024) Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy. Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2024.01.001","journal-title":"Eur J Intern Med"},{"key":"2522_CR113","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/aps.2018.38","volume":"39","author":"M Luciani","year":"2018","unstructured":"Luciani M, Troncone L, Monte FD (2018) Current and future circulating biomarkers for cardiac amyloidosis. Acta Pharmacol Sin 39:1133\u20131141. https:\/\/doi.org\/10.1038\/aps.2018.38","journal-title":"Acta Pharmacol Sin"},{"key":"2522_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123178","author":"NPE Kadoglou","year":"2023","unstructured":"Kadoglou NPE, Khattab E, Velidakis N, Gkougkoudi E (2023) The Role of osteopontin in atherosclerosis and its clinical manifestations (atherosclerotic cardiovascular diseases)-a narrative review. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11123178","journal-title":"Biomedicines"},{"key":"2522_CR115","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3109\/13506129.2014.940457","volume":"21","author":"AV Kristen","year":"2014","unstructured":"Kristen AV et al (2014) Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid 21:202\u2013210. https:\/\/doi.org\/10.3109\/13506129.2014.940457","journal-title":"Amyloid"},{"key":"2522_CR116","doi-asserted-by":"publisher","first-page":"110885","DOI":"10.1016\/j.diabres.2023.110885","volume":"203","author":"A Scuricini","year":"2023","unstructured":"Scuricini A et al (2023) Osteopontin levels correlate with severity of diabetic cardiomyopathy in early stage of diabetes. Diabetes Res Clin Pract 203:110885. https:\/\/doi.org\/10.1016\/j.diabres.2023.110885","journal-title":"Diabetes Res Clin Pract"},{"key":"2522_CR117","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/aas.14145","volume":"67","author":"PT Pekkarinen","year":"2023","unstructured":"Pekkarinen PT et al (2023) Markers of neutrophil mediated inflammation associate with disturbed continuous electroencephalogram after out of hospital cardiac arrest. Acta Anaesthesiol Scand 67:94\u2013103. https:\/\/doi.org\/10.1111\/aas.14145","journal-title":"Acta Anaesthesiol Scand"},{"key":"2522_CR118","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1038\/bcj.2015.45","volume":"5","author":"E Kastritis","year":"2015","unstructured":"Kastritis E et al (2015) Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the mayo staging. Blood Cancer J 5:e319. https:\/\/doi.org\/10.1038\/bcj.2015.45","journal-title":"Blood Cancer J"},{"key":"2522_CR119","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3109\/07853890.2012.727019","volume":"45","author":"M Montagnana","year":"2013","unstructured":"Montagnana M, Lippi G, Danese E, Guidi GC (2013) The role of osteoprotegerin in cardiovascular disease. Ann Med 45:254\u2013264. https:\/\/doi.org\/10.3109\/07853890.2012.727019","journal-title":"Ann Med"},{"key":"2522_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.07.033","author":"HH Luan","year":"2019","unstructured":"Luan HH et al (2019) GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. https:\/\/doi.org\/10.1016\/j.cell.2019.07.033","journal-title":"Cell"},{"key":"2522_CR121","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/gerona\/glab011","volume":"76","author":"J Tavenier","year":"2021","unstructured":"Tavenier J et al (2021) Association of GDF15 With inflammation and physical function during aging and recovery after acute hospitalization: a longitudinal study of older patients and age-matched controls. J Gerontol A Biol Sci Med Sci 76:964\u2013974. https:\/\/doi.org\/10.1093\/gerona\/glab011","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2522_CR122","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","volume":"131","author":"E Kastritis","year":"2018","unstructured":"Kastritis E et al (2018) Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood 131:1568\u20131575. https:\/\/doi.org\/10.1182\/blood-2017-12-819904","journal-title":"Blood"},{"key":"2522_CR123","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jacc.2021.12.017","volume":"79","author":"L Liberale","year":"2022","unstructured":"Liberale L et al (2022) Inflammation, aging, and cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol 79:837\u2013847. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.017","journal-title":"J Am Coll Cardiol"},{"key":"2522_CR124","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","volume":"128","author":"E Kastritis","year":"2016","unstructured":"Kastritis E et al (2016) Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood 128:405\u2013409. https:\/\/doi.org\/10.1182\/blood-2016-02-702696","journal-title":"Blood"},{"key":"2522_CR125","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ajh.24001","volume":"90","author":"A Dispenzieri","year":"2015","unstructured":"Dispenzieri A et al (2015) Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol 90:524\u2013528. https:\/\/doi.org\/10.1002\/ajh.24001","journal-title":"Am J Hematol"},{"key":"2522_CR126","doi-asserted-by":"publisher","first-page":"e005868","DOI":"10.1161\/JAHA.112.005868","volume":"2","author":"K Tanaka","year":"2013","unstructured":"Tanaka K et al (2013) Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc 2:e005868. https:\/\/doi.org\/10.1161\/JAHA.112.005868","journal-title":"J Am Heart Assoc"},{"key":"2522_CR127","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","volume":"1","author":"A Biolo","year":"2008","unstructured":"Biolo A et al (2008) Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 1:249\u2013257. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.108.788687","journal-title":"Circ Heart Fail"},{"key":"2522_CR128","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4330\/wjc.v13.i3.55","volume":"13","author":"SJ Hein","year":"2021","unstructured":"Hein SJ et al (2021) Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. World J Cardiol 13:55\u201367. https:\/\/doi.org\/10.4330\/wjc.v13.i3.55","journal-title":"World J Cardiol"},{"key":"2522_CR129","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock TP, Yan T, Chang E, Guthrie S, Broder MS (2018) Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv 2:1046\u20131053. https:\/\/doi.org\/10.1182\/bloodadvances.2018016402","journal-title":"Blood Adv"},{"key":"2522_CR130","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13681","volume":"107","author":"S Oubari","year":"2021","unstructured":"Oubari S et al (2021) Impact of time to diagnosis on mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. Eur J Haematol 107:449\u2013457. https:\/\/doi.org\/10.1111\/ejh.13681","journal-title":"Eur J Haematol"},{"key":"2522_CR131","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaccao.2022.08.011","volume":"4","author":"MC Minnema","year":"2022","unstructured":"Minnema MC et al (2022) Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial. JACC CardioOncol 4:474\u2013487. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.011","journal-title":"JACC CardioOncol"},{"key":"2522_CR132","doi-asserted-by":"publisher","first-page":"1212983","DOI":"10.3389\/fcvm.2023.1212983","volume":"10","author":"P Morfino","year":"2023","unstructured":"Morfino P et al (2023) Cardiovascular toxicity from therapies for light chain amyloidosis. Front Cardiovasc Med 10:1212983. https:\/\/doi.org\/10.3389\/fcvm.2023.1212983","journal-title":"Front Cardiovasc Med"},{"key":"2522_CR133","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E et al (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"2522_CR134","doi-asserted-by":"publisher","first-page":"1073503","DOI":"10.3389\/fcvm.2022.1073503","volume":"9","author":"CC Quarta","year":"2022","unstructured":"Quarta CC et al (2022) Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy. Front Cardiovasc Med 9:1073503. https:\/\/doi.org\/10.3389\/fcvm.2022.1073503","journal-title":"Front Cardiovasc Med"},{"key":"2522_CR135","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/13506129.2019.1582486","volume":"26","author":"E Muchtar","year":"2019","unstructured":"Muchtar E et al (2019) Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid 26:101\u2013102. https:\/\/doi.org\/10.1080\/13506129.2019.1582486","journal-title":"Amyloid"},{"key":"2522_CR136","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","volume":"26","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P et al (2024) Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail 26:397\u2013410. https:\/\/doi.org\/10.1002\/ejhf.3138","journal-title":"Eur J Heart Fail"},{"key":"2522_CR137","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS et al (2023) Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 389:1553\u20131565. https:\/\/doi.org\/10.1056\/NEJMoa2300757","journal-title":"N Engl J Med"},{"key":"2522_CR138","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"2522_CR139","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"2522_CR140","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 390:132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"2522_CR141","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G et al (2020) Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail 26:753\u2013759. https:\/\/doi.org\/10.1016\/j.cardfail.2019.11.024","journal-title":"J Card Fail"},{"key":"2522_CR142","doi-asserted-by":"publisher","first-page":"B99","DOI":"10.1093\/eurheartjsupp\/suad082","volume":"25","author":"MT Mallus","year":"2023","unstructured":"Mallus MT, Rizzello V (2023) Treatment of amyloidosis: present and future. Eur Heart J Suppl 25:B99\u2013B103. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad082","journal-title":"Eur Heart J Suppl"},{"key":"2522_CR143","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD et al (2021) CRISPR-cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"2522_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010284","author":"S Ney","year":"2024","unstructured":"Ney S et al (2024) Multiparametric monitoring of disease progression in contemporary patients with wild-type transthyretin amyloid cardiomyopathy initiating tafamidis treatment. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13010284","journal-title":"J Clin Med"},{"key":"2522_CR145","doi-asserted-by":"publisher","first-page":"100720","DOI":"10.1016\/j.blre.2020.100720","volume":"45","author":"C Varga","year":"2021","unstructured":"Varga C et al (2021) The diagnostic challenges of cardiac amyloidosis: a practical approach to the two main types. Blood Rev 45:100720. https:\/\/doi.org\/10.1016\/j.blre.2020.100720","journal-title":"Blood Rev"},{"key":"2522_CR146","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","volume":"32","author":"E Muchtar","year":"2018","unstructured":"Muchtar E et al (2018) Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia 32:2240\u20132249. https:\/\/doi.org\/10.1038\/s41375-018-0060-x","journal-title":"Leukemia"},{"key":"2522_CR147","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.2023021311","volume":"142","author":"A Huart","year":"2023","unstructured":"Huart A (2023) Birtamimab: a new amyloidosis treatment? Blood 142:1178\u20131180. https:\/\/doi.org\/10.1182\/blood.2023021311","journal-title":"Blood"},{"key":"2522_CR148","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P et al (2023) Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med 389:239\u2013250. https:\/\/doi.org\/10.1056\/NEJMoa2303765","journal-title":"N Engl J Med"},{"key":"2522_CR149","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/blood.2020009039","volume":"138","author":"CV Edwards","year":"2021","unstructured":"Edwards CV et al (2021) Phase 1a\/b study of monoclonal antibody CAEL-101 (11\u20131F4) in patients with AL amyloidosis. Blood 138:2632\u20132641. https:\/\/doi.org\/10.1182\/blood.2020009039","journal-title":"Blood"},{"key":"2522_CR150","doi-asserted-by":"publisher","first-page":"25080","DOI":"10.1038\/srep25080","volume":"6","author":"NJ Galant","year":"2016","unstructured":"Galant NJ et al (2016) Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses. Sci Rep 6:25080. https:\/\/doi.org\/10.1038\/srep25080","journal-title":"Sci Rep"},{"key":"2522_CR151","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood.2022019406","volume":"142","author":"MA Gertz","year":"2023","unstructured":"Gertz MA et al (2023) Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood 142:1208\u20131218. https:\/\/doi.org\/10.1182\/blood.2022019406","journal-title":"Blood"},{"key":"2522_CR152","doi-asserted-by":"publisher","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","volume":"25","author":"M Emdin","year":"2023","unstructured":"Emdin M et al (2023) Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. Eur Heart J Suppl 25:B79\u2013B84. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad079","journal-title":"Eur Heart J Suppl"},{"key":"2522_CR153","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMc2304584","volume":"388","author":"M Fontana","year":"2023","unstructured":"Fontana M et al (2023) Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy. N Engl J Med 388:2199\u20132201. https:\/\/doi.org\/10.1056\/NEJMc2304584","journal-title":"N Engl J Med"},{"key":"2522_CR154","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","volume":"44","author":"A Ioannou","year":"2023","unstructured":"Ioannou A et al (2023) Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J 44:2893\u20132907. https:\/\/doi.org\/10.1093\/eurheartj\/ehad347","journal-title":"Eur Heart J"},{"key":"2522_CR155","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13506129.2021.1981281","volume":"29","author":"A Briasoulis","year":"2022","unstructured":"Briasoulis A et al (2022) Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid 29:31\u201337. https:\/\/doi.org\/10.1080\/13506129.2021.1981281","journal-title":"Amyloid"},{"key":"2522_CR156","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","volume":"25","author":"E Muchtar","year":"2018","unstructured":"Muchtar E et al (2018) Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 25:86\u201392. https:\/\/doi.org\/10.1080\/13506129.2018.1449744","journal-title":"Amyloid"},{"key":"2522_CR157","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.amjcard.2023.07.140","volume":"204","author":"CL Yan","year":"2023","unstructured":"Yan CL et al (2023) Safety and efficacy of traditional heart failure therapies in patients with cardiac amyloidosis and heart failure. Am J Cardiol 204:360\u2013365. https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.140","journal-title":"Am J Cardiol"},{"key":"2522_CR158","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3198","author":"FM Lang","year":"2024","unstructured":"Lang FM et al (2024) Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3198","journal-title":"Eur J Heart Fail"},{"key":"2522_CR159","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ejhf.1902","volume":"22","author":"M Packer","year":"2020","unstructured":"Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA (2020) Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 22:1551\u20131567. https:\/\/doi.org\/10.1002\/ejhf.1902","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02522-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02522-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:02:46Z","timestamp":1776279766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02522-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":159,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2522"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02522-2","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20140155","asserted-by":"subject"}]},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LL is co-inventor on the international patent WO\/2020\/226993 filed in April 2020. The patent relates to the use of antibodies which specifically bind IL-1\n                      \u03b1\n                      to reduce various sequelae of ischaemia\u2013reperfusion injury to the central nervous system. LL reports speaker fees from Daiichi-Sankyo outside the submitted work, he is counsellor of the European Society for Clinical Investigation and has received funding from the Novartis Foundation for Medical-biological Research, the Swiss Heart Foundation, the Italian Ministry of Health (unrelated to this work). AG is co-founder and shareholder of Kither Biotech, a pharmaceutical company focused on the development of PI3K inhibitors for airway diseases not in conflict with the content of this work. MC received speaker and advisor fees in the last 2\u00a0years from Akcea Therapeutics, Alnylam, Amicus Therapeutics, Astrazeneca, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi e Sanofi Genzyme, Takeda and two investigator-initiated grants from Pfizer. CM received (speaker and consultancy) honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novo Nordisk, Edwards, Novartis, Pfizer, Servier, all outside the current work. The other authors report nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}